Home Awareness CHMP Grants Favorable Opinion: Bristol Myers Melanoma

CHMP Grants Favorable Opinion: Bristol Myers Melanoma

Bristol Myers Squibb announces that the European Medicines Agency’s CHMP has recommended approval of Opdivo as an adjuvant therapy for patients 12 years of age and older with completely resected stage IIB or IIC melanoma.

This positive opinion is based on safety and efficacy results from the Phase 3 CheckMate -76K trial, in which, with a minimum follow-up of 7.8 months, Opdivo reduced the risk of recurrence or death by 58% compared to placebo.

These results were presented at the 2022 annual meeting of the Society for Melanoma Research (SMR). The European Commission, which has the power to approve medicines in the European Union, will now review the CHMP recommendation.

This article is originally published on boursorama.com

Related Articles


Anti-dumping investigation in China: French cognac suspended from Macron-Xi discussions

The French cognac industry, which says it is “hostage” to tensions between...


Subject of tensions between France and China: the Cognac industry awaits a diplomatic solution

Since January, cognac has been targeted, like all wine spirits imported from...


Senegal: Diomaye Faye wants to build “a renovated partnership” with the European Union

Arriving in Senegal on Monday, the President of the European Council notes...


Beijing denies any ‘alleged Chinese espionage’ after arrest in Germany

“The theory of the threat of alleged Chinese espionage is not a...